Molecular Pharmacology Stock Probability of Future Pink Sheet Price Finishing Over 9.6E-5
| MLPH Stock | USD 0.0001 0.00 0.00% |
Molecular |
Molecular Pharmacology Target Price Odds to finish over 9.6E-5
The tendency of Molecular Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 0.000096 in 90 days |
| 0.0001 | 90 days | 0.000096 | about 78.3 |
Based on a normal probability distribution, the odds of Molecular Pharmacology to stay above $ 0.000096 in 90 days from now is about 78.3 (This Molecular Pharmacology probability density function shows the probability of Molecular Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Molecular Pharmacology price to stay between $ 0.000096 and its current price of $1.0E-4 at the end of the 90-day period is near 1 .
Given the investment horizon of 90 days Molecular Pharmacology has a beta of -0.17. This indicates as returns on the benchmark increase, returns on holding Molecular Pharmacology are expected to decrease at a much lower rate. During a bear market, however, Molecular Pharmacology is likely to outperform the market. Additionally Molecular Pharmacology has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Molecular Pharmacology Price Density |
| Price |
Predictive Modules for Molecular Pharmacology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Molecular Pharmacology. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Molecular Pharmacology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Molecular Pharmacology is not an exception. The market had few large corrections towards the Molecular Pharmacology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Molecular Pharmacology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Molecular Pharmacology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.93 | |
β | Beta against Dow Jones | -0.17 | |
σ | Overall volatility | 0.0004 | |
Ir | Information ratio | -0.09 |
Molecular Pharmacology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Molecular Pharmacology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Molecular Pharmacology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Molecular Pharmacology generated a negative expected return over the last 90 days | |
| Molecular Pharmacology has high historical volatility and very poor performance | |
| Molecular Pharmacology has some characteristics of a very speculative penny stock | |
| Molecular Pharmacology has a very high chance of going through financial distress in the upcoming years | |
| Molecular Pharmacology currently holds 175.33 K in liabilities. Molecular Pharmacology has a current ratio of 0.27, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Molecular Pharmacology until it has trouble settling it off, either with new capital or with free cash flow. So, Molecular Pharmacology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Molecular Pharmacology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Molecular to invest in growth at high rates of return. When we think about Molecular Pharmacology's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (116.93 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Molecular Pharmacology currently holds about 1.52 K in cash with (105.41 K) of positive cash flow from operations. |
Molecular Pharmacology Technical Analysis
Molecular Pharmacology's future price can be derived by breaking down and analyzing its technical indicators over time. Molecular Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Molecular Pharmacology. In general, you should focus on analyzing Molecular Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Molecular Pharmacology Predictive Forecast Models
Molecular Pharmacology's time-series forecasting models is one of many Molecular Pharmacology's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Molecular Pharmacology's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Molecular Pharmacology
Checking the ongoing alerts about Molecular Pharmacology for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Molecular Pharmacology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Molecular Pharmacology generated a negative expected return over the last 90 days | |
| Molecular Pharmacology has high historical volatility and very poor performance | |
| Molecular Pharmacology has some characteristics of a very speculative penny stock | |
| Molecular Pharmacology has a very high chance of going through financial distress in the upcoming years | |
| Molecular Pharmacology currently holds 175.33 K in liabilities. Molecular Pharmacology has a current ratio of 0.27, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Molecular Pharmacology until it has trouble settling it off, either with new capital or with free cash flow. So, Molecular Pharmacology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Molecular Pharmacology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Molecular to invest in growth at high rates of return. When we think about Molecular Pharmacology's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (116.93 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Molecular Pharmacology currently holds about 1.52 K in cash with (105.41 K) of positive cash flow from operations. |
Other Information on Investing in Molecular Pink Sheet
Molecular Pharmacology financial ratios help investors to determine whether Molecular Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Molecular with respect to the benefits of owning Molecular Pharmacology security.